fampridine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4163	504-24-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fampyra dalfampridine ampyra pyridin-4-amine 4-aminopyridine fampridine	One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes. Molecular weight: 94.12 Formula: C5H6N2 CLOGP: 0.32 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 38.91 ALOGS: 0.46 ROTB: 0

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	90.30 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.04 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	2.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 22, 2010	FDA	ACORDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	1628.26	14.25	739	34330	41386	46609607
Urinary tract infection	1302.61	14.25	1172	33897	219094	46431899
Gait disturbance	1264.72	14.25	968	34101	144295	46506698
Laboratory test abnormal	997.36	14.25	437	34632	22410	46628583
Multiple sclerosis	859.88	14.25	404	34665	24387	46626606
Balance disorder	697.22	14.25	491	34578	64030	46586963
Urine analysis abnormal	596.84	14.25	191	34878	3999	46646994
Fall	505.87	14.25	892	34177	328205	46322788
Therapy cessation	384.53	14.25	243	34826	26386	46624607
Muscular weakness	330.19	14.25	375	34694	91469	46559524
Seizure	231.17	14.25	366	34703	122688	46528305
Insomnia	209.37	14.25	413	34656	164511	46486482
Escherichia urinary tract infection	205.74	14.25	116	34953	10207	46640786
Muscle spasticity	199.89	14.25	118	34951	11322	46639671
Gait inability	167.51	14.25	167	34902	35036	46615957
Rheumatoid arthritis	165.60	14.25	3	35066	240212	46410781
Peroneal nerve palsy	153.81	14.25	71	34998	4097	46646896
B-lymphocyte count decreased	153.61	14.25	46	35023	764	46650229
Inappropriate schedule of product administration	145.52	14.25	210	34859	64803	46586190
Dizziness	139.21	14.25	564	34505	339850	46311143
Drug ineffective	138.31	14.25	924	34145	676914	45974079
Central nervous system lesion	136.83	14.25	87	34982	9528	46641465
Toxicity to various agents	133.74	14.25	6	35063	211760	46439233
Secondary progressive multiple sclerosis	131.17	14.25	45	35024	1175	46649818
Lymphocyte count decreased	128.42	14.25	125	34944	25464	46625529
Therapeutic response unexpected	128.29	14.25	101	34968	15515	46635478
Hypoaesthesia	126.39	14.25	277	34792	118592	46532401
Culture urine positive	125.87	14.25	58	35011	3333	46647660
Memory impairment	120.88	14.25	212	34857	77125	46573868
Urine leukocyte esterase positive	115.34	14.25	50	35019	2485	46648508
Dyspnoea	106.73	14.25	139	34930	515409	46135584
Paraesthesia	106.43	14.25	257	34812	117180	46533813
Flushing	106.02	14.25	181	34888	64433	46586560
Mobility decreased	101.08	14.25	171	34898	60423	46590570
Micturition urgency	97.20	14.25	65	35004	7752	46643241
Anaemia	96.19	14.25	36	35033	255743	46395250
Asthenia	93.63	14.25	471	34598	310604	46340389
Pollakiuria	90.27	14.25	101	34968	24160	46626833
Walking aid user	85.11	14.25	50	35019	4750	46646243
Completed suicide	80.82	14.25	8	35061	145912	46505081
JC polyomavirus test positive	78.95	14.25	29	35040	928	46650065
T-lymphocyte count increased	78.04	14.25	18	35051	98	46650895
Urinary incontinence	77.10	14.25	101	34968	28429	46622564
Off label use	76.84	14.25	104	34965	379737	46271256
Lymphopenia	75.39	14.25	74	34995	15219	46635774
Head injury	74.12	14.25	92	34977	24544	46626449
Acute kidney injury	73.54	14.25	43	35026	235812	46415181
CD4 lymphocytes increased	72.18	14.25	18	35051	143	46650850
T-lymphocyte count decreased	71.67	14.25	20	35049	255	46650738
Progressive multiple sclerosis	69.06	14.25	25	35044	767	46650226
Trigeminal neuralgia	68.94	14.25	37	35032	2952	46648041
Neurogenic bladder	64.27	14.25	35	35034	2875	46648118
Product substitution issue	61.87	14.25	66	35003	14965	46636028
Motor dysfunction	61.75	14.25	48	35021	7234	46643759
Dysstasia	61.39	14.25	71	34998	17597	46633396
Depression	59.31	14.25	269	34800	169835	46481158
Influenza like illness	58.66	14.25	132	34937	57438	46593555
Red blood cells urine positive	56.59	14.25	31	35038	2576	46648417
Neutropenia	55.74	14.25	19	35050	143185	46507808
Hypotension	54.07	14.25	57	35012	232532	46418461
White blood cells urine positive	53.16	14.25	35	35034	4065	46646928
Exposure during pregnancy	52.55	14.25	9	35060	108203	46542790
Pneumonia	52.03	14.25	130	34939	376190	46274803
CD4 lymphocytes decreased	51.94	14.25	25	35044	1585	46649408
CD8 lymphocytes decreased	50.72	14.25	14	35055	171	46650822
Febrile neutropenia	50.31	14.25	6	35063	94621	46556372
Dysgraphia	49.28	14.25	29	35040	2763	46648230
Drug hypersensitivity	48.97	14.25	67	35002	243758	46407235
Adverse drug reaction	48.91	14.25	105	34964	44257	46606736
Diarrhoea	48.03	14.25	237	34832	559365	46091628
Temperature intolerance	47.51	14.25	42	35027	7565	46643428
Gait spastic	47.00	14.25	14	35055	228	46650765
Epilepsy	46.37	14.25	72	34997	23666	46627327
Product dose omission issue	46.26	14.25	249	34820	168271	46482722
Loss of control of legs	46.19	14.25	22	35047	1362	46649631
Dysuria	44.34	14.25	77	34992	27756	46623237
Primary progressive multiple sclerosis	44.26	14.25	11	35058	86	46650907
Lymphocyte count abnormal	43.92	14.25	17	35052	630	46650363
Progressive multifocal leukoencephalopathy	43.51	14.25	48	35021	11298	46639695
Gastrointestinal haemorrhage	43.46	14.25	4	35065	77369	46573624
Haemoglobin urine present	43.44	14.25	17	35052	649	46650344
Ataxia	41.86	14.25	52	35017	13878	46637115
Escherichia test positive	41.57	14.25	23	35046	1949	46649044
Arthralgia	41.55	14.25	138	34931	364465	46286528
Movement disorder	41.46	14.25	57	35012	16792	46634201
Full blood count abnormal	40.95	14.25	21	35048	1526	46649467
Vomiting	40.40	14.25	189	34880	452605	46198388
Burning sensation	39.95	14.25	97	34972	44314	46606679
Vitamin B12 increased	39.78	14.25	15	35054	517	46650476
Wheelchair user	39.71	14.25	29	35040	3979	46647014
Drug interaction	39.57	14.25	57	35012	203037	46447956
Magnetic resonance imaging abnormal	39.53	14.25	25	35044	2711	46648282
Hemiparesis	39.37	14.25	61	35008	20008	46630985
Pancytopenia	39.32	14.25	8	35061	85050	46565943
Optic neuritis	39.10	14.25	36	35033	6835	46644158
Abdominal pain	38.79	14.25	71	34998	229960	46421033
Muscle spasms	38.70	14.25	189	34880	122924	46528069
Nitrite urine present	38.44	14.25	16	35053	718	46650275
Urine odour abnormal	38.41	14.25	31	35038	4931	46646062
Pleural effusion	37.93	14.25	8	35061	82944	46568049
Respiratory failure	37.90	14.25	12	35057	94804	46556189
General symptom	37.77	14.25	23	35046	2332	46648661
Systemic lupus erythematosus	37.61	14.25	3	35066	65177	46585816
Urine abnormality	37.18	14.25	32	35037	5562	46645431
Cognitive disorder	36.92	14.25	84	34985	36799	46614194
Joint swelling	34.99	14.25	44	35025	166029	46484964
Intentional overdose	34.81	14.25	4	35065	64940	46586053
Generalised tonic-clonic seizure	34.37	14.25	68	35001	27054	46623939
Urinary tract infection bacterial	34.33	14.25	27	35042	4138	46646855
B-lymphocyte count abnormal	34.32	14.25	8	35061	46	46650947
Feeling abnormal	33.76	14.25	184	34885	124876	46526117
Cardiac arrest	33.46	14.25	13	35056	90386	46560607
Prescribed underdose	33.07	14.25	43	35026	12010	46638983
Urinary tract infection pseudomonal	32.94	14.25	15	35054	838	46650155
Platelet count decreased	32.92	14.25	17	35052	100007	46550986
Tremor	32.47	14.25	172	34897	115467	46535526
Hyponatraemia	32.21	14.25	18	35051	101314	46549679
Infusion related reaction	32.14	14.25	18	35051	101190	46549803
Tongue biting	31.78	14.25	17	35052	1347	46649646
Death	31.72	14.25	137	34932	335411	46315582
Thrombocytopenia	31.71	14.25	29	35040	126552	46524441
Acute disseminated encephalomyelitis	31.65	14.25	10	35059	200	46650793
Musculoskeletal disorder	31.55	14.25	48	35021	15497	46635496
Product use issue	31.27	14.25	16	35053	94628	46556365
Fatigue	30.58	14.25	633	34436	608064	46042929
Ankle fracture	30.22	14.25	47	35022	15464	46635529
Lymphocyte percentage decreased	30.13	14.25	21	35048	2678	46648315
Cystitis	29.55	14.25	84	34985	42157	46608836
Extra dose administered	29.42	14.25	26	35043	4681	46646312
Decreased appetite	29.09	14.25	64	35005	193772	46457221
Blood immunoglobulin M decreased	29.03	14.25	13	35056	698	46650295
Treatment failure	28.92	14.25	17	35052	93070	46557923
Hypokinesia	28.91	14.25	39	35030	11283	46639710
Insurance issue	27.59	14.25	17	35052	1761	46649232
Bladder disorder	27.24	14.25	30	35039	7048	46643945
Glycosylated haemoglobin increased	27.07	14.25	37	35032	10839	46640154
Invasive ductal breast carcinoma	27.01	14.25	28	35041	6140	46644853
Immune reconstitution inflammatory syndrome	26.91	14.25	27	35042	5698	46645295
Coordination abnormal	26.88	14.25	37	35032	10912	46640081
Psoriasis	26.40	14.25	13	35056	78591	46572402
Overdose	25.97	14.25	23	35046	101956	46549037
Hypoxia	25.85	14.25	4	35065	51834	46599159
Pyrexia	25.81	14.25	155	34914	348647	46302346
Contraindicated product administered	25.70	14.25	14	35055	79933	46571060
Sinusitis	25.67	14.25	36	35033	129732	46521261
Lymphocyte percentage abnormal	25.49	14.25	5	35064	10	46650983
Cardiac failure congestive	25.47	14.25	19	35050	91731	46559262
Status epilepticus	25.36	14.25	41	35028	13938	46637055
Hyperkalaemia	25.09	14.25	4	35065	50705	46600288
Weight increased	24.92	14.25	54	35015	164419	46486574
Bacterial test positive	24.86	14.25	23	35046	4393	46646600
International normalised ratio increased	24.84	14.25	3	35066	46880	46604113
Urinary sediment present	24.73	14.25	16	35053	1804	46649189
Product use in unapproved indication	24.67	14.25	19	35050	90254	46560739
Asthma	24.10	14.25	20	35049	91522	46559471
Maternal exposure during pregnancy	23.94	14.25	25	35044	102524	46548469
Headache	23.81	14.25	497	34572	477855	46173138
Paraparesis	23.80	14.25	16	35053	1923	46649070
Tachycardia	23.58	14.25	24	35045	99598	46551395
Plasma cell myeloma	23.19	14.25	3	35066	44475	46606518
Rash	23.04	14.25	165	34904	356347	46294646
Cardiac failure	22.92	14.25	16	35053	79932	46571061
Oxygen saturation decreased	22.39	14.25	12	35057	69152	46581841
Human papilloma virus test positive	22.39	14.25	9	35060	369	46650624
Urine ketone body present	22.36	14.25	16	35053	2126	46648867
Stress	22.18	14.25	87	34982	51464	46599529
Lower respiratory tract infection	21.96	14.25	7	35062	55082	46595911
Protein urine present	21.95	14.25	23	35046	5108	46645885
Proteus test positive	21.79	14.25	7	35062	148	46650845
Electrocardiogram QT prolonged	21.41	14.25	6	35063	51319	46599674
Muscle tightness	21.17	14.25	32	35037	10273	46640720
Renal failure	21.02	14.25	33	35036	113561	46537432
Cystitis klebsiella	21.00	14.25	7	35062	167	46650826
Incontinence	20.79	14.25	31	35038	9831	46641162
Anaphylactic reaction	20.73	14.25	7	35062	53105	46597888
Urinary tract infection enterococcal	20.63	14.25	16	35053	2402	46648591
Skin laceration	20.62	14.25	44	35025	18458	46632535
Relapsing-remitting multiple sclerosis	20.54	14.25	9	35060	459	46650534
Diplopia	20.32	14.25	45	35024	19360	46631633
Red blood cell count abnormal	20.21	14.25	11	35058	902	46650091
Cardio-respiratory arrest	19.96	14.25	10	35059	59859	46591134
Multiple organ dysfunction syndrome	19.86	14.25	7	35062	51703	46599290
Hypoglycaemia	19.80	14.25	8	35061	54341	46596652
Limb discomfort	19.68	14.25	49	35020	22727	46628266
Feeling hot	19.67	14.25	68	35001	37860	46613133
Disease progression	19.41	14.25	24	35045	91276	46559717
Urinary retention	19.38	14.25	53	35016	26008	46624985
Lower limb fracture	19.35	14.25	34	35035	12364	46638629
Metabolic acidosis	19.32	14.25	3	35066	38777	46612216
Rhabdomyolysis	19.24	14.25	4	35065	41905	46609088
Stomatitis	19.14	14.25	14	35055	68283	46582710
Initial insomnia	19.12	14.25	20	35049	4432	46646561
Postictal paralysis	19.02	14.25	5	35064	50	46650943
Hip fracture	18.75	14.25	53	35016	26503	46624490
Bone pain	18.62	14.25	6	35063	46884	46604109
Atrial fibrillation	18.32	14.25	31	35038	103559	46547434
Ascites	17.85	14.25	3	35066	36581	46614412
Urinary tract infection staphylococcal	17.82	14.25	7	35062	270	46650723
Transferrin saturation decreased	17.42	14.25	8	35061	456	46650537
Pain	17.41	14.25	253	34816	476695	46174298
Blood thyroid stimulating hormone decreased	17.27	14.25	18	35051	3971	46647022
Neuropathy peripheral	17.20	14.25	26	35043	90867	46560126
Neutrophil percentage increased	17.11	14.25	15	35054	2672	46648321
Oedema peripheral	17.09	14.25	62	35007	159644	46491349
Sensory disturbance	17.06	14.25	32	35037	12235	46638758
Decreased interest	16.94	14.25	16	35053	3136	46647857
Postictal state	16.72	14.25	10	35059	981	46650012
Bronchitis	16.71	14.25	34	35035	105945	46545048
Chronic kidney disease	16.64	14.25	5	35064	40866	46610127
Therapeutic response changed	16.59	14.25	9	35060	733	46650260
Mean cell haemoglobin increased	16.58	14.25	13	35056	1983	46649010
Bladder dysfunction	16.53	14.25	9	35060	739	46650254
Migraine without aura	16.51	14.25	6	35063	186	46650807
CD4 lymphocyte percentage decreased	16.51	14.25	3	35066	3	46650990
Focal dyscognitive seizures	16.45	14.25	15	35054	2813	46648180
Urge incontinence	16.43	14.25	9	35060	748	46650245
Hepatic function abnormal	16.40	14.25	3	35066	34418	46616575
Dehydration	16.38	14.25	63	35006	159477	46491516
Infection	16.26	14.25	49	35020	133543	46517450
Injection site scar	16.17	14.25	9	35060	771	46650222
Mean cell haemoglobin decreased	16.07	14.25	15	35054	2897	46648096
Weight decreased	15.93	14.25	93	34976	210756	46440237
Dyspnoea exertional	15.88	14.25	9	35060	50280	46600713
Breast cancer	15.83	14.25	72	34997	45446	46605547
Suicide attempt	15.79	14.25	11	35058	55025	46595968
Haematocrit abnormal	15.78	14.25	9	35060	808	46650185
Depressed level of consciousness	15.77	14.25	8	35061	47561	46603432
Cough	15.62	14.25	105	34964	230144	46420849
Citrobacter infection	15.56	14.25	7	35062	380	46650613
Vitamin D increased	15.54	14.25	7	35062	381	46650612
Vitamin D decreased	15.49	14.25	24	35045	7869	46643124
Glossodynia	15.42	14.25	7	35062	44366	46606627
General physical health deterioration	15.16	14.25	41	35028	115728	46535265
Urinary tract disorder	15.16	14.25	13	35056	2247	46648746
Eye contusion	15.14	14.25	11	35058	1497	46649496
Therapeutic product effect incomplete	15.13	14.25	22	35047	78131	46572862
Coma	15.04	14.25	13	35056	58336	46592657
Specific gravity urine abnormal	14.98	14.25	3	35066	7	46650986
Hypokalaemia	14.96	14.25	27	35042	87997	46562996
Pulmonary oedema	14.95	14.25	10	35059	51095	46599898
Neutrophil count increased	14.86	14.25	33	35036	14220	46636773
Arthritis	14.74	14.25	22	35047	77294	46573699
Blood thyroid stimulating hormone increased	14.66	14.25	20	35049	5849	46645144
Glucose urine present	14.61	14.25	8	35061	664	46650329
B-lymphocyte count increased	14.56	14.25	5	35064	131	46650862
Back pain	14.54	14.25	230	34839	209809	46441184
Haematochezia	14.53	14.25	5	35064	37488	46613505
Decreased vibratory sense	14.38	14.25	6	35063	271	46650722

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	818.26	20.76	258	11019	10604	29930597
Gait disturbance	532.01	20.76	337	10940	74440	29866761
Multiple sclerosis	527.69	20.76	168	11109	7099	29934102
Laboratory test abnormal	326.77	20.76	150	11127	17292	29923909
Urinary tract infection	286.12	20.76	230	11047	73429	29867772
Balance disorder	235.22	20.76	155	11122	36338	29904863
Drug ineffective	217.88	20.76	426	10851	339961	29601240
Fall	217.08	20.76	302	10975	181570	29759631
Muscular weakness	147.95	20.76	149	11128	63496	29877705
Muscle spasticity	140.77	20.76	58	11219	5130	29936071
B-lymphocyte count decreased	102.87	20.76	26	11251	464	29940737
Mobility decreased	102.31	20.76	82	11195	25917	29915284
Therapy cessation	99.07	20.76	65	11212	15072	29926129
Insomnia	99.07	20.76	147	11130	93189	29848012
Secondary progressive multiple sclerosis	94.55	20.76	23	11254	348	29940853
Seizure	87.61	20.76	143	11134	98332	29842869
Gait inability	71.08	20.76	58	11219	18783	29922418
Flushing	68.30	20.76	69	11208	29423	29911778
Central nervous system lesion	66.93	20.76	34	11243	4872	29936329
Therapeutic response unexpected	60.12	20.76	39	11238	8864	29932337
Product substitution issue	58.22	20.76	40	11237	9995	29931206
Influenza like illness	55.83	20.76	58	11219	25547	29915654
Peroneal nerve palsy	55.17	20.76	24	11253	2425	29938776
Trigeminal neuralgia	54.10	20.76	18	11259	870	29940331
Acute kidney injury	54.01	20.76	18	11259	273824	29667377
Memory impairment	53.62	20.76	68	11209	37106	29904095
Anaemia	52.28	20.76	8	11269	207984	29733217
Progressive multifocal leukoencephalopathy	50.11	20.76	35	11242	8978	29932223
JC polyomavirus test positive	48.52	20.76	15	11262	571	29940630
Movement disorder	47.21	20.76	35	11242	9848	29931353
Hypotension	45.49	20.76	10	11267	200555	29740646
Lymphocyte count decreased	44.87	20.76	45	11232	19010	29922191
Ataxia	44.73	20.76	36	11241	11426	29929775
Inappropriate schedule of product administration	44.10	20.76	64	11213	39664	29901537
Toxicity to various agents	39.83	20.76	9	11268	177174	29764027
Paraesthesia	37.93	20.76	71	11206	54256	29886945
Drug interaction	37.78	20.76	14	11263	199554	29741647
Asthenia	37.08	20.76	173	11104	221117	29720084
Relapsing-remitting multiple sclerosis	36.41	20.76	10	11267	249	29940952
Lymphocyte percentage decreased	36.07	20.76	17	11260	2069	29939132
Full blood count abnormal	35.71	20.76	14	11263	1086	29940115
White blood cells urine positive	35.48	20.76	14	11263	1105	29940096
Gait spastic	35.32	20.76	9	11268	166	29941035
Urine analysis abnormal	34.71	20.76	16	11261	1852	29939349
Urinary incontinence	34.47	20.76	37	11240	16903	29924298
Vitamin B12 increased	33.24	20.76	9	11268	212	29940989
Renal failure	32.27	20.76	5	11272	128961	29812240
Walking aid user	32.00	20.76	14	11263	1433	29939768
Paraparesis	31.90	20.76	15	11262	1816	29939385
Dizziness	31.61	20.76	151	11126	194758	29746443
CD8 lymphocytes decreased	30.92	20.76	7	11270	76	29941125
Cognitive disorder	30.51	20.76	41	11236	23649	29917552
Neutropenia	29.95	20.76	6	11271	128534	29812667
Progressive multiple sclerosis	29.09	20.76	8	11269	200	29941001
T-lymphocyte count decreased	29.06	20.76	8	11269	201	29941000
Dyspnoea	28.81	20.76	51	11226	333244	29607957
Decreased vibratory sense	28.42	20.76	9	11268	371	29940830
Back pain	27.47	20.76	93	11184	102503	29838698
Adverse drug reaction	26.71	20.76	38	11239	23107	29918094
Hypoaesthesia	26.25	20.76	61	11216	54169	29887032
Cystitis	25.88	20.76	23	11254	8351	29932850
Thrombocytopenia	25.27	20.76	10	11267	137034	29804167
General symptom	25.02	20.76	10	11267	816	29940385
Micturition urgency	24.23	20.76	17	11260	4390	29936811
Dysstasia	23.25	20.76	24	11253	10481	29930720
Muscle spasms	23.14	20.76	65	11212	64773	29876428
Bladder disorder	22.98	20.76	14	11263	2849	29938352
Urosepsis	22.82	20.76	24	11253	10708	29930493
Musculoskeletal stiffness	22.70	20.76	45	11232	35836	29905365
Depression	22.48	20.76	80	11197	90357	29850844
Spinal cord injury cauda equina	21.97	20.76	6	11271	146	29941055
Pancytopenia	21.96	20.76	3	11274	85049	29856152
Somatosensory evoked potentials abnormal	21.82	20.76	6	11271	150	29941051
Cardiac failure	21.40	20.76	3	11274	83415	29857786
Neurogenic bladder	21.31	20.76	11	11266	1628	29939573
Product dose omission issue	21.04	20.76	79	11198	91552	29849649
Vitamin B6 deficiency	20.84	20.76	6	11271	178	29941023

Pharmacologic Action:

Source	Code	Description
ATC	N07XX07	NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS Other nervous system drugs
FDA MoA	N0000175448	Potassium Channel Antagonists
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D026902	Potassium Channel Blockers
FDA EPC	N0000192795	Potassium Channel Blocker
CHEBI has role	CHEBI:33289	avicides
CHEBI has role	CHEBI:71031	orphan drugs

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Multiple sclerosis	indication	24700007	DOID:2377
Seizure disorder	contraindication	128613002
Impaired renal function disorder	contraindication	197663003

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.58	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Voltage-gated potassium channel	Ion channel	O43525 O43526 O95259 P16389 P17658 P22001 P22459 P22460 P48547 P51787 P56696 Q03721 Q09470 Q12809 Q14003 Q14721 Q16322 Q6PIU1 Q8NCM2 Q8TAE7 Q8TDN1 Q8TDN2 Q92953 Q96KK3 Q96L42 Q96PR1 Q96RP8 Q9BQ31 Q9H252 Q9H3M0 Q9NR82 Q9NS40 Q9NSA2 Q9NZV8 Q9UIX4 Q9UJ96 Q9UK17 Q9ULD8 Q9ULS6 Q9UQ05	KCA10_HUMAN KCNA1_HUMAN KCNA2_HUMAN KCNA3_HUMAN KCNA4_HUMAN KCNA5_HUMAN KCNA6_HUMAN KCNA7_HUMAN KCNB1_HUMAN KCNB2_HUMAN KCNC1_HUMAN KCNC2_HUMAN KCNC3_HUMAN KCNC4_HUMAN KCND1_HUMAN KCND2_HUMAN KCND3_HUMAN KCNF1_HUMAN KCNG1_HUMAN KCNG2_HUMAN KCNG3_HUMAN KCNG4_HUMAN KCNH1_HUMAN KCNH2_HUMAN KCNH3_HUMAN KCNH4_HUMAN KCNH5_HUMAN KCNH6_HUMAN KCNH7_HUMAN KCNH8_HUMAN KCNQ1_HUMAN KCNQ2_HUMAN KCNQ3_HUMAN KCNQ4_HUMAN KCNQ5_HUMAN KCNS1_HUMAN KCNS2_HUMAN KCNS3_HUMAN KCNV1_HUMAN KCNV2_HUMAN	BLOCKER				CHEMBL	CHEMBL
Potassium voltage-gated channel subfamily C member 1	Unclassified		KCNC1_MOUSE	BLOCKER	IC50	4.50		IUPHAR
Potassium voltage-gated channel subfamily C member 2	Unclassified		KCNC2_RAT	BLOCKER	IC50	4.60		IUPHAR

External reference:

ID	Source
4029704	VUID
N0000180628	NUI
D04127	KEGG_DRUG
4025700	VANDF
4025705	VANDF
4029704	VANDF
C0000477	UMLSCUI
CHEBI:34385	CHEBI
4AP	PDB_CHEM_ID
CHEMBL284348	ChEMBL_ID
1727	PUBCHEM_CID
DB06637	DRUGBANK_ID
D015761	MESH_DESCRIPTOR_UI
2416	IUPHAR_LIGAND_ID
7283	INN_ID
BH3B64OKL9	UNII
897018	RXNORM
170373	MMSL
26967	MMSL
NOCODE	MMSL
d07546	MMSL
006829	NDDF
413355004	SNOMEDCT_US
80994002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0479	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	27 sections
dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0509	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	NDA authorized generic	27 sections
AMPYRA	HUMAN PRESCRIPTION DRUG LABEL	1	10144-427	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	NDA	27 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	16729-292	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
DALFAMPRIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-275	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-246	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
Dalfampridine	Human Prescription Drug Label	1	62756-429	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	27 sections
DALFAMPRIDINE	Human Prescription Drug Label	1	65862-863	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Dalfampridine	Human Prescription Drug Label	1	67877-444	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections